1.   A specific leukotriene receptor antagonist awaits development.

2.   However, the effect of specific inhibition of platelet activating factor by a specific receptor antagonist has so far been evaluated in models of experimental colitis only.

3.   The possible therapeutic effect of a specific receptor antagonist in inflammatory bowel disease remains to be evaluated.

4.   Such effects may be blocked by administration of histamine receptor antagonists, such as cimetidine.

5.   The drug is a so-called epidermal growth factor receptor antagonist.